CNSP
CNS Pharmaceuticals, Inc.Company Information
- Company Name
- CNS Pharmaceuticals, Inc.
- CIK
- CIK0001729427
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- CNSP: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- CNSP
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-05-18
- Last sale
- —
- Shares purchased (TTM)
- 9,100
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 1,584,782
- Shares outstanding
- 6,838,205
- Ownership
- 23.18%
Earnings Market Reaction
- Filing date
- 2026-08-12
- Price on filing date
- —
- 1-month reaction
- 14.37%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 20 | 3 | 7 | 10 | 12 | 13 | 6 | 7 | 1 | 1 | 1 | 1 | ||||||
| Deferred Offering Costs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Common Stock Share Subscribed But Unissued Subscriptions Receivable | - | - | 0 | - | - | - | 1 | - | - | - | 0 | - | ||||||
| Prepaid Expense And Other Assets Current | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | ||||||
| Assets Current | 22 | 4 | 8 | 11 | 14 | 14 | 9 | 7 | 2 | 2 | 2 | 2 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Prepaid Expense Noncurrent | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets Noncurrent | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 22 | 5 | 9 | 12 | 15 | 14 | 9 | 7 | 2 | 2 | 2 | 2 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 4 | 4 | 4 | 2 | 1 | 3 | 2 | 4 | 7 | 6 | 6 | 4 | ||||||
| Notes Payable Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Current | 4 | 5 | 4 | 2 | 1 | 3 | 3 | 4 | 7 | 6 | 6 | 4 | ||||||
| Liabilities | 4 | 5 | 4 | 2 | 1 | 3 | 3 | 4 | 7 | 6 | 6 | 4 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 126 | 105 | 105 | 104 | 104 | 100 | 91 | 85 | 71 | 69 | 65 | 62 | ||||||
| Retained Earnings Accumulated Deficit | -108 | -105 | -100 | -94 | -91 | -89 | -84 | -81 | -76 | -73 | -70 | -64 | ||||||
| Stockholders Equity | 18 | 0 | 5 | 10 | 13 | 11 | 6 | 3 | -4 | -4 | -4 | -2 | ||||||
| Liabilities And Stockholders Equity | 22 | 5 | 9 | 12 | 15 | 14 | 9 | 7 | 2 | 2 | 2 | 2 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 0 | 0 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 300 | 300 | 25 | 25 | 300 | 300 | 300 | 300 | 300 | 75 | 300 | 75 | ||||||
| Common Stock Shares Issued | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | ||||||
| Shares Outstanding | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialCNS Pharmaceuticals, Inc. (CNSP) — SEC Financial Statements & Analysis
CNS Pharmaceuticals, Inc. (CNSP) is a pharmaceutical preparations company, incorporated in NV. CNS Pharmaceuticals, Inc. trades on Nasdaq as: CNSP. CNS Pharmaceuticals, Inc. (CNSP)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12. Based on that filing, CNS Pharmaceuticals, Inc. carries a market cap of $32.69M, a P/E ratio of -1.96x, a P/B ratio of 1.80x, a P/S ratio of 340.40x, an enterprise value of $12.70M, and an EV/EBITDA multiple of -0.75x. On profitability, it posts a gross margin of 143.56%, an operating margin of -221392.71%, a net margin of -220736.90%, a Return on Equity (ROE) of -106.62%, and a Return on Assets (ROA) of -91.64%. Per share, it reports EPS of $-2.44, diluted EPS of $-2.44, free cash flow per share of $-1.96, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of 8.03% year-over-year, and EPS growth of -94.15% year-over-year. On the balance sheet, it maintains a current ratio of 5.86x, a quick ratio of 5.37x, working capital of $18.18M, a debt-to-equity ratio of 0.21x, a debt ratio of 0.17, an interest coverage ratio of -1117.76x, free cash flow of $-13.42M (TTM), and net debt of $-19.98M. Figures sourced from SEC EDGAR.
- Market Cap
- $32.69M
- P/E TTM
- -1.96x
- EPS TTM
- $-2.44
- P/B TTM
- 1.80x
- ROE TTM
- -106.62%
- ROA TTM
- -91.64%
- Debt To Equity
- 0.21x
- Free Cash Flow TTM
- $-13.42M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is CNS Pharmaceuticals, Inc. in?
CNS Pharmaceuticals, Inc. (CNSP) operates in the Pharmaceutical Preparations industry.
What exchange does CNSP trade on?
CNS Pharmaceuticals, Inc. (CNSP) trades on the Nasdaq.
Where is CNS Pharmaceuticals, Inc. incorporated?
CNS Pharmaceuticals, Inc. is incorporated in NV.
When was CNS Pharmaceuticals, Inc. (CNSP)'s most recent SEC filing?
CNS Pharmaceuticals, Inc. (CNSP)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12.
What is CNSP's market cap?
CNS Pharmaceuticals, Inc. (CNSP) has a market capitalization of $32.69M as of 2026-06-30.
What is CNSP's EPS (earnings per share)?
CNS Pharmaceuticals, Inc. (CNSP)'s trailing twelve month EPS is $-2.44 as of 2026-06-30.
What is CNSP's ROE (return on equity)?
CNS Pharmaceuticals, Inc. (CNSP)'s trailing twelve month Return on Equity (ROE) is -106.62% as of 2026-06-30.
What is CNSP's ROA (return on assets)?
CNS Pharmaceuticals, Inc. (CNSP)'s trailing twelve month Return on Assets (ROA) is -91.64% as of 2026-06-30.
What is CNSP's EV/EBITDA?
CNS Pharmaceuticals, Inc. (CNSP)'s trailing twelve month EV/EBITDA is -0.75x as of 2026-06-30.